Monitoring Giant Cell Arteritis During Treatment Tapering
Part of Brain & nervous system, Heart & circulation, Immune system & allergy, Skin clinical trials.
This study tracks patients with giant cell arteritis (GCA, a blood vessel inflammation affecting older adults) who are in remission and tapering their steroid medications. Researchers will monitor disease activity through blood tests and patient questionnaires to understand if their condition stays stable as they reduce treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with GCA by a rheumatologist with confirmed imaging or biopsy within the past 3 years
- Currently in remission: on stable or tapering steroids for at least 8 weeks with no worsening GCA symptoms
- Normal inflammation blood test (CRP < 10 mg/L) within the past week
- Age 50 or older
- Able to speak, read, and understand Danish
- Able to complete online questionnaires and commit to ongoing monitoring during medication tapering
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses ultrasound, a biopsy of the temple artery, and blood tests to improve how giant cell arteritis (GCA) is diagnosed, monitored, and predicted. It may help doctors find better ways to manage this condition.
This study compares stopping tocilizumab (Actemra) completely versus reducing the dose in people whose giant cell arteritis has been well controlled for at least a year. The goal is to find out which approach keeps the disease in remission while reducing medication side effects.
This trial tests if a shorter course of the steroid prednisone, combined with tocilizumab, works as well as a longer course for giant cell arteritis. You must already be starting tocilizumab and taking at least 20 mg of prednisone daily.
This study measures how C-reactive protein (CRP), a marker of inflammation, changes in people with giant cell arteritis after they start taking steroids. It aims to understand the body's response to treatment and help guide future care.
This study tests whether bosentan, a medicine usually used for blood pressure in the lungs, can help control inflammation and symptoms in patients with giant cell arteritis (GCA). The goal is to see if it can reduce the need for steroids and improve quality of life.
This study is for people with giant cell arteritis (GCA), a condition where blood vessels become inflamed. It tests a drug called rituximab to see if it can help by targeting special immune cells (B cells). The study uses scans to look at inflammation in the large blood vessels. You must have active GCA in the large vessels (shown by a scan in the last 4 weeks), be over 50, and start treatment with steroids alone (no other immune-suppressing drugs yet). You cannot have been on steroids for more than 4 weeks before joining.
Hear when a new Giant Cell Arteritis (GCA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.